Expert Highlights Biologics in the Pipeline for Eczema : vim

Dr David Rosmarin reviewed several biologics in clinical trials that target interleukin-4 and other receptors.

Related Keywords

Keymed Biosciences , David Rosmarin , European Academy Of Dermatology , Indiana University , Revolutionizing Atopic Dermatitis , Eczema Area , Severity Index , Investigator Global Assessment , Dermatitis , Biologic Therapy , Iologics , Receptors , Atopic Dermatitis , Atopic Eczema , Interleukins , Monoclonal Antibody , Etuximab , Ituximab , Pruritus , Pruritis , Pitch , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Healthcare Technology , Medical Technology , Clinical Research , Clinical Trials , Linical Studies , Pre Clinical Trial ,